Prothena's fair value estimate has recently risen from $13 to $16.50, signaling renewed confidence in the company's prospects. This revised price target reflects analyst optimism about the near-term ...

Using the 2 Stage Free Cash Flow to Equity, Babcock & Wilcox Enterprises fair value estimate is US$9.71 Babcock & Wilcox Enterprises' US$5.15 share price signals that it might be 47% undervalued ...